Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection

Ram Yogev*, Sophia Lee, Andrew Wiznia, Sharon Nachman, Kenneth Stanley, Stephen Pelton, Lynne Mofenson, Susan Fiscus, Eleanor Jimenez, Mobeen H. Rathore, Mary Elizabeth Smith, Lin Ye Song, Kenneth Mcintosh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background. The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine (d4T), nevirapine (NVP) and ritonavir (RTV) has not been determined. Aim. To evaluate the safety, tolerance, antiviral activity and immunologic changes after the change to a three drug combination. Methods. During a clinical trial in which HIV-infected antiretroviral-experienced children were initially randomized to receive d4T/RTV, ZDV/3TC/RTV or ZDV/3TC (Step 1), 48 children who had HIV RNA ≥10 000 copies/ml after ≥12 weeks of ZDV/3TC therapy in Step 1 were switched to d4T/NVP/RTV in Step 2. The proportion of children receiving therapy with HIV RNA ≤400 copies/ml at Study Weeks 24 and 48 receiving d4T/NVP/RTV in Step 2 were compared with children receiving RTV-containing regimens in Step 1. Results. At 24 weeks of treatment with d4T/NVP/RTV in Step 2,48% (23 of 48) of children had HIV RNA ≤400 copies/ml compared with 34% (31 of 92) and 47% (44 of 93) receiving d4T/RTV or ZDV/3TC/RTV for 24 weeks in Step 1; at 48 weeks virologic response was 44, 27 and 42% in Step 2 d4T/NVP/RTV, Step 1 d4T/RTV and Step 1 ZDV/3TC/RTV arms, respectively. Conclusions. A delay of 7 to 12 months in the initiation of protease inhibitor-containing combination therapy in children receiving dual nucleoside analogue therapy did not adversely affect the RNA response during the first 48 weeks of treatment.

Original languageEnglish (US)
Pages (from-to)119-125
Number of pages7
JournalPediatric Infectious Disease Journal
Volume21
Issue number2
DOIs
StatePublished - 2002

Keywords

  • Children
  • Human immunodeficiency virus
  • Lamivudine
  • Nevirapine
  • Nucleoside analogue reverse transcriptase inhibitor
  • Protease inhibitor
  • Ritonavir
  • Stavudine
  • Zidovudine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection'. Together they form a unique fingerprint.

Cite this